OPKO Health sells NGENLA growth hormone treatment, Rayaldee kidney disease treatment and specialty lab tests for doctors and patients. It last closed at $1.62 on Nov 17, up 0.00% on the day. OPK last reported earnings on Mon, Jul 27, 2026.
Only 1 firm rated OPK in the past 90 days, not enough for a consensus
Average 12-month target
$4.00
▲ 146.9% upside
Based on 1 analyst who set a price target on OPK in the past 90 days. The average target is $4.00, with a high of $4.00 and a low of $4.00, compared with the last close of $1.62.
Low $4.00Avg $4.00High $4.00
Blue marker: last close $1.62
Highest target$4.00
Average target$4.00
Lowest target$4.00
Latest rating changes
Piper SandlerReiterated
Oct 16Buy$4
Date
Firm
Action
Rating
Price target
Oct 16
Piper Sandler
Reiterated
Buy
$4
Loading…
Technical Analysis
OPK · as of the Nov 17 close · updated after every close
Moving sideways
The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 47). The nearest support is the 50 day average at $1.60, and the nearest resistance the Pivot R1 at $1.65.
Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityHigh, 4.9%/day
Key levels
$1.8652 week high+14.8%
$1.6720 day average+3.1%
$1.67Swing high (Oct 26)+3.1%
$1.65Pivot R1+1.9%
$1.62Pivot+0.0%
$1.62Last close
$1.6050 day average−1.2%
$1.59Pivot S1−1.9%
$1.59Swing low (Oct 28)−1.9%
$1.50100 day average−7.4%
$1.37200 day average−15.4%
$0.9852 week low−39.5%
Indicators
RSI (14)
47.02
Middle of its range
Neutral
MACD
0.02
Below its signal line
Bearish
Stochastic
18.5
Near the bottom of its range
Oversold
ADX (14)
25.8
Trending down
Williams %R
-88.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-83.8
Oversold below −100, overbought above 100
Neutral
Rate of change
−5.8%
Change over 10 sessions
Bearish
ATR (14)
$0.08
Typical daily range, 4.9% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
Uptrend
Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityNormal, 10.6%/day
Key levels
$1.8652 week high+14.8%
$1.6720 day average+3.1%
$1.67Swing high (Oct 26)+3.1%
$1.65Pivot R1+1.9%
$1.62Pivot+0.0%
$1.62Last close
$1.6050 day average−1.2%
$1.59Pivot S1−1.9%
$1.59Swing low (Oct 28)−1.9%
$1.50100 day average−7.4%
$1.37200 day average−15.4%
$0.9852 week low−39.5%
Indicators
RSI (14)
56.10
Middle of its range
Neutral
MACD
0.09
Above its signal line
Bullish
Stochastic
67.5
Middle of its range
Neutral
ADX (14)
31.5
Trending up
Williams %R
-42.9
Oversold below −80, overbought above −20
Neutral
CCI (20)
60.0
Oversold below −100, overbought above 100
Neutral
Rate of change
+3.2%
Change over 10 sessions
Bullish
ATR (14)
$0.17
Typical daily range, 10.6% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for OPK
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OPK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow OPK usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OPK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OPK is in one of them and how their past OPK trades turned out.
OPKO Health is a healthcare company based in Miami, Florida. It sells NGENLA, a weekly growth hormone treatment for children, and Rayaldee, a treatment for secondary hyperparathyroidism in adults with chronic kidney disease. Its laboratory business provides clinical and women's health testing in New York and New Jersey, along with the 4Kscore prostate cancer test, which is offered across the United States. The company is also developing therapies for cancer and infectious disease.